EyePoint, Inc. reported $2.8M of revenue over the trailing twelve months, −95% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $2.8M (to Q2 2026). Net income: −$307M, trailing twelve months to Q2 2026. Free cash flow: −$271M, trailing twelve months to Q2 2026. Operating margin: −12377%, trailing twelve months to Q2 2026.

EYPTEyePoint, Inc.

Healthcare

$3.40-74% 1Y

$3.40

$3.1552 weeks$18.85

EYPT as reported

EyePoint, Inc. reported $2.8M of revenue over the trailing twelve months, −95% on the year before. 9 reported series are charted on this page, each one as filed.

$2.8M

Revenue, trailing twelve months · to Q2 2026 · −95% against the twelve months before

Net income: −$307M
Net income · +75% year on year · trailing twelve months to Q2 2026
Free cash flow: −$271M
Free cash flow · +40% year on year · trailing twelve months to Q2 2026
Operating margin: −12377%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for EYPT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$2.8M	−95%	Q2 2026
Net income	−$307M	+75%	Q2 2026
EPS	−$3.75	+39%	Q2 2026
Operating margin	−12377%	n/a	Q2 2026
Net margin	−11977%	n/a	Q2 2026
ROE	−120%	n/a	Q2 2026
ROA	−94%	n/a	Q2 2026
ROIC	289%	n/a	Q4 2023 · 10 quarters behind
Free cash flow	−$271M	+40%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.